(NASDAQ: ZBIO) Zenas Biopharma's forecast annual revenue growth rate of 113.03% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.8%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.37%.
Zenas Biopharma's revenue in 2026 is $10,000,000.On average, 9 Wall Street analysts forecast ZBIO's revenue for 2026 to be $829,787,987, with the lowest ZBIO revenue forecast at $0, and the highest ZBIO revenue forecast at $4,271,062,058. On average, 9 Wall Street analysts forecast ZBIO's revenue for 2027 to be $2,961,619,215, with the lowest ZBIO revenue forecast at $792,617,891, and the highest ZBIO revenue forecast at $5,454,539,575.
In 2028, ZBIO is forecast to generate $5,636,087,963 in revenue, with the lowest revenue forecast at $1,665,254,739 and the highest revenue forecast at $10,769,002,952.